<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04167553</url>
  </required_header>
  <id_info>
    <org_study_id>HM-GCG-102</org_study_id>
    <nct_id>NCT04167553</nct_id>
  </id_info>
  <brief_title>Phase 1, for Multiple Doses of HM15136 in Obese or Overweight Subjects With Comorbidities</brief_title>
  <official_title>A Phase 1, Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of HM15136 in Obese or Overweight Subjects With Comorbidities</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hanmi Pharmaceutical Company Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hanmi Pharmaceutical Company Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The planned period of each cohort is 22 weeks including subject screening, treatments for 12
      weeks, and follow up period.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 30, 2019</start_date>
  <completion_date type="Anticipated">December 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>adverse events (AEs):</measure>
    <time_frame>after multiple subcutaneous (SC) doses for 12 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Obese or Overweight Subjects With Comorbidities</condition>
  <arm_group>
    <arm_group_label>HM15136</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HM15136</intervention_name>
    <description>In Part 1, approximately 36 subjects, divided into 3 cohorts with 12 subjects (HM15136 group 9 subjects, placebo group 3 subjects) per cohort. In Part 2, approximately 36 subjects, divided in 2 cohorts with 18 subjects (HM15136 group 9 subjects, placebo group 9 subjects) per cohort. However, Part 2 study may not be conducted after the review of the safety data in Part 1.</description>
    <arm_group_label>HM15136</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>In Part 1, approximately 36 subjects, divided into 3 cohorts with 12 subjects (HM15136 group 9 subjects, placebo group 3 subjects) per cohort. In Part 2, approximately 36 subjects, divided in 2 cohorts with 18 subjects (HM15136 group 9 subjects, placebo group 9 subjects) per cohort. However, Part 2 study may not be conducted after the review of the safety data in Part 1.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or Female subjects

          2. Age ≥ 18 to ≤ 65 years at Screening visit

          3. Body Mass Index ( BMI ≥ 30 kg/m 2 or 27 kg/m 2 with presence of comorbidities
             (Subjects in Part 1 and Subjects with Pre diabete s mellitus (DM) in Part 2:
             dyslipidemia and or hypertension except for Type 2 (T2) DM, T2DM subjects in Part 2:
             dyslipidemia and/or hypertension with T2DM) with/without medication treatment and have
             had stable weight for 3 months (weight changes less than 5%)

        Exclusion Criteria:

          1. Previous surgical treatment for obesity (bariatric surgery, gastric banding, etc.) or
             any other gastrointestinal surgery that may induce malabsorption, history of bowel
             resection &gt; 20 cm, any malabsorption disorder, severe gastroparesis, any GI procedure
             for weight loss (including LAPBAND®), as well as clinically significant
             gastrointestinal disorders (e.g. peptic ulcers, severe GERD ) at Screening.

          2. Use of antacids, anticoagulants, or drugs that directly modify gastrointestinal (GI)
             motility, including antacid s anticholinergics, anticonvulsants, serotonin type 3
             (5HT3) antagonists, dopamine antagonists, opiates; anticoagulation within 2 weeks of
             screening (But, it is not limited to the above listed drugs.)

          3. Uncontrolled hypertension, defined as systolic blood pressure &gt; 160 mmHg and/or
             diastolic blood pressure ≥ 100 mmHg at screening independent of subjects being on
             antihypertensive medication or no t). But, if the results are out of the reference
             range at the screening visit, they can be tested again on another day. Subjects with
             uncontrolled hypertension may be rescreened after 3 months, following initiation or
             adjustment of antihyp ertensive therapy.)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kyounghee Seo</last_name>
    <phone>02-410-9042</phone>
    <email>khseo.@hanmi.co.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Prosciento</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>91911</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prosciento</last_name>
    </contact>
    <investigator>
      <last_name>Hanmi Clinical</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 15, 2019</study_first_submitted>
  <study_first_submitted_qc>November 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 19, 2019</study_first_posted>
  <last_update_submitted>November 15, 2019</last_update_submitted>
  <last_update_submitted_qc>November 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

